Hepatitis/MASH

Rina Shah, PharmD, Vice President, Pharmacy Operations and Specialty Pharmacy, Walgreens, explores the benefits of incorporating specialty pharmacists into care teams.

Differences in major risk factors and inequalities in health care access have resulted in substantial disparities in liver cancer mortality.

How NS5A inhibitors block hepatitis C virus replication impacts treatment outcomes.

Research team will seek to develop a novel prophylactic vaccine to prevent HCV.

HCV drug greatly reduced the rates of liver transplants and mortality in patients with advanced stages of cirrhosis.

The contaminated fish was sourced from Sustainable Seafood Company and Santa Cruz Seafood.

Wider access to new direct-acting antivirals for people who inject drugs may help reduce HCV infections.

Patient genotypes of in both hepatitis C and advanced cirrhosis may help predict outcomes with direct-acting antiviral drugs.

Study provides picture of host cell pathway mobilization to HCV.

In this clip, Jennifer Strohecker, PharmD, BCPS, Sr. Director MHI Pharmacy, Clinical Operations, Molina Healthcare, Inc. discusses the challenges involved in treating patients with hepatitis C.

In this clip, Jennifer Strohecker, PharmD, BCPS, who is Senior Director MHI Pharmacy, Clinical Operations, discusses a high touch model of care.

The Guide to Hepatitis C Testing addresses widespread uncertainty regarding HCV treatment.

The Guide to Hepatitis C Testing summarizes the latest examination recommendations.

The criminalization of drug use could be detrimental to HIV patient health and does not decrease use, study suggests.

Chronic hepatitis C virus (HCV) infection, estimated to affect up to 4 million Americans, is a leading cause of end-stage liver disease, hepatocellular carcinoma, and liver transplant.

Hepatitis C virus infection rates are the highest in 15 years, according to recent data released by the CDC.

Chronic hepatitis B virus is still a problem in many parts of the world and the United States, despite the availability of a vaccine.

Top news of the day from across the health care landscape.

Chronic hepatitis B (HBV) is still a problem in many parts of the world and the United States, despite the availability of a vaccine.

World Health Organization reports lack of uptake of hepatitis treatments.

Eating animal protein may increase the risk of non-alcoholic fatty liver disease development.

Patients who received kidney transplants from donors infected with hepatitis C virus were cured after antiviral drug therapy.

Direct-acting antiviral agents have the potential to substantially increase the number of kidney transplants by making infected kidneys available.

Opioid epidemic fuels hepatitis C transmission.

Ledipasvir/sofosbuvir combination resulted in beneficial viral response in pediatric patients.